Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Colchicine for CABG Graft Failure Prevention
NCT07569328Not yet recruiting
- Sponsor
- Beijing An Zhen Hospital
- Start
- Sep 2026
- Primary completion
- Sep 2028
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Randomised, double-blind trial in coronary artery disease (CAD) comparing Colchicine group with Placebo group (2 arms). Primary endpoint: Graft Failure Rate at 2 years. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
colchicine
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT07569328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07569328.